Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in Alcohol Use Disorder With Comorbid Depression
NCT06235411Completed
- Sponsor
- CHU Nîmes
- Start
- Feb 2024
- Primary completion
- Nov 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of psilocybin in alcohol use disorder (AUD) and major depressive disorder (MDD) (2 arms), sponsored by CHU Nîmes. Primary endpoint: Feasibility of the intervention between groups at Week 4. Started Feb 2024; status: completed.
02
Drugs
psilocybin
03
Conditions
alcohol use disorder (AUD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06235411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235411.